WO2003035849A3 - Methods for gene transfer using pseudotyped lentiviruses - Google Patents

Methods for gene transfer using pseudotyped lentiviruses Download PDF

Info

Publication number
WO2003035849A3
WO2003035849A3 PCT/US2002/034545 US0234545W WO03035849A3 WO 2003035849 A3 WO2003035849 A3 WO 2003035849A3 US 0234545 W US0234545 W US 0234545W WO 03035849 A3 WO03035849 A3 WO 03035849A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycoprotein
glycoproteins
virus
togaviral
filoviral
Prior art date
Application number
PCT/US2002/034545
Other languages
French (fr)
Other versions
WO2003035849A2 (en
Inventor
Paul B Mccray Jr
David A Sanders
Beverly L Davidson
Original Assignee
Paul B Mccray Jr
David A Sanders
Beverly L Davidson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul B Mccray Jr, David A Sanders, Beverly L Davidson filed Critical Paul B Mccray Jr
Priority to AU2002348103A priority Critical patent/AU2002348103A1/en
Publication of WO2003035849A2 publication Critical patent/WO2003035849A2/en
Publication of WO2003035849A3 publication Critical patent/WO2003035849A3/en
Priority to US10/811,353 priority patent/US20050112098A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Methods for introducing nucleic acid sequences into hepatocytes, brain glial cells and airway epithelial cell are provided. The methods use filoviral and togaviral glycoprotein-pseudotyped lentiviruses. The viruses comprise a lentiviral capsid and a viral envelope further comprising a lipid bilayer and a functional filoviral glycoprotein or two functional togaviral glycoproteins. In one embodiment the lentivirus is a feline immunodeficiency virus (FIV). In an alternate embodiment, the filoviral glycoprotein is a Marburg virus glycoprotein. In another embodiment, the Marburg virus glycoprotein can have a mutation in the C-terminal portion of the amino acid sequence that results in a higher titer production of the pseudotyped virus. In an alternate embodiment the togaviral glycoproteins are alphavirus glycoproteins, for example, the E1 and the E2 envelope glycoproteins of Ross River virus (RRV).
PCT/US2002/034545 2001-10-26 2002-10-28 Methods for gene transfer using pseudotyped lentiviruses WO2003035849A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002348103A AU2002348103A1 (en) 2001-10-26 2002-10-28 Methods for gene transfer using pseudotyped lentiviruses
US10/811,353 US20050112098A1 (en) 2001-10-26 2004-03-26 Pseudotyped viruses and methods for their use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35643601P 2001-10-26 2001-10-26
US35322101P 2001-10-26 2001-10-26
US60/353,221 2001-10-26
US60/356,436 2001-10-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/811,353 Continuation-In-Part US20050112098A1 (en) 2001-10-26 2004-03-26 Pseudotyped viruses and methods for their use

Publications (2)

Publication Number Publication Date
WO2003035849A2 WO2003035849A2 (en) 2003-05-01
WO2003035849A3 true WO2003035849A3 (en) 2003-10-30

Family

ID=26997853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/034545 WO2003035849A2 (en) 2001-10-26 2002-10-28 Methods for gene transfer using pseudotyped lentiviruses

Country Status (2)

Country Link
AU (1) AU2002348103A1 (en)
WO (1) WO2003035849A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981656B2 (en) 2002-06-04 2011-07-19 Purdue Research Foundation Pseudotyped retrovirus with modified ebola glycoprotein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008131A2 (en) * 1998-08-04 2000-02-17 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008131A2 (en) * 1998-08-04 2000-02-17 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production

Also Published As

Publication number Publication date
WO2003035849A2 (en) 2003-05-01
AU2002348103A1 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
Jacks et al. Two efficient ribosomal frameshifting events are required for synthesis of mouse mammary tumor virus gag-related polyproteins.
Haas et al. Codon usage limitation in the expression of HIV-1 envelope glycoprotein
Jeffers et al. Covalent modifications of the ebola virus glycoprotein
Kaye et al. Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation
ATE291632T1 (en) LENTIVIRUS-BASED GENE TRANSFER VECTORS
Pique et al. Mutations introduced along the HTLV‐I envelope gene result in a non‐functional protein: a basis for envelope conservation?
WO1999027958A3 (en) Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination
AU3988799A (en) Novel lentiviral packaging cells
AU2234995A (en) Feline immunodeficiency virus vaccine
EP2339010A3 (en) Lentiviral vector particles resistant to complement inactivation
Pietschmann et al. An evolutionarily conserved positively charged amino acid in the putative membrane-spanning domain of the foamy virus envelope protein controls fusion activity
KR920703118A (en) Vectors with multiple target response factors that affect gene expression
AU7234987A (en) Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody
Chen et al. Cytoplasmic tail truncation of SARS-CoV-2 spike protein enhances titer of pseudotyped vectors but masks the effect of the D614G mutation
Delos et al. Critical role for the cysteines flanking the internal fusion peptide of avian sarcoma/leukosis virus envelope glycoprotein
Virnik et al. Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques
DK0975783T3 (en) Retroviral vectors, their method of preparation and their use for gene transfer to CD4 positive cells
WO2003035849A3 (en) Methods for gene transfer using pseudotyped lentiviruses
CN116554349A (en) Chimeric virus envelope glycoprotein and vector comprising same
AU8188187A (en) Viral vector and recombinant DNA coding, in particular, for the p25 protein of the virus that is a causal agent of aids, infected cell culture, protein obtained, vaccine and antibodies obtained
RU2006123079A (en) VIRUS PARTICLES CONTAINING A VECTOR ORIGINING FROM ALPHAVIRUS AND METHOD FOR PRODUCING THE SPECIFIED VIRUS PARTICLE
WO2001046408A2 (en) Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
Chevalier et al. Construction and characterization of a human T-cell lymphotropic virus type 3 infectious molecular clone
JP2003517839A5 (en)
Chevalier et al. Construction and characterization of a full-length infectious simian T-cell lymphotropic virus type 3 molecular clone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP